Diego Tomassone received Master’s degrees in Medicine and Surgery (Ita), Chemistry (UK), and Physics(UK), and Bachelor’s degree in Mathematics (SW), as well as PhD in Infectious diseases, Microbiology and Public Health (UK).

He works at “Holos medica” clinical and research as a clinical physician and researcher with expertise in immunology, genetics and infectious diseases, and as a theoretical physicist with expertise in quantum physics and biophysics at the “Foundation of physics research center”.

Ts. Dr. Liew Kai Bin is the head of department of Pharmaceutical Technology and Industry, Faculty of Pharmacy, University of Cyberjaya (UoC). He obtained his Bachelor’s degree in Pharmacy, Master in Science (Pharmaceutical Technology), and Doctor of Philosophy (Pharmaceutical Technology) from Universiti Sains Malaysia (USM). He has experience in various pharmaceutical related fields including research and development, product development, bioequivalence study, analytical chemistry, regulatory affair and public health pharmacy.

He has published more than 50 publications in international journals and books chapter. He has been repeatedly invited as speaker to deliver speeches in neighboring countries. His research areas focus on the novel drug delivery system, orally disintegrating dosage forms, bioequivalence study and self microemulsifying system.

Dr. Minxia Fan obtained his Ph.D. from Wuhan Botanical Garden, Chinese Academy of Sciences in 2020. The research interests of Dr. Minxia Fan have ranged from the development of new strategies (like multiple drug targets based bio-affinity screening and multi-omics approaches) for the quick screening and identification of bioactive compounds to the in-depth study and exploration of their mechanisms of action from resourceful medicinal plants.

Dr. Daniel Looi Qi Hao is the Chief Scientific Officer of My CytoHealth Sdn. Bhd. At the same time, he is also appointed as an Honorary Lecturer in University Malaysia and Adjunct Lecturer in the Faculty of Medicine, MAHSA University. He has published more than 20 papers in international peer-reviewed journals and 3 patents on exosome isolation from stem cell and downstream application of exosome. Dr. Daniel also served as editor for several international scientific journals. Currently, Dr. Daniel is focusing in the clinical development of cell-based therapy and biomaterial for dermatological and orthopedic application such as knee joint injury and wound care management.

Dr. Daniel is also a member of various professional bodies including Tissue Engineering and Regenerative Medicine Society of Malaysia (TESMA), Tissue Engineering and Regenerative Medicine Society (TERMIS), Stem Cell Society Singapore (SCSS) as well as serving as a council member of Malaysian Society for Stem Cell Research and Therapy. Besides of research and academic, Dr. Daniel also provided medical advices for several companies in the field of medicine management.

Dr. Sunil Chaudhry has over 40 years of experience as a Pharmacologist in Academics and the Pharmaceutical Industry ( Clinical development & Pharmacovigilance )

He is Honorary Director with Bioclinitech Technologies Pvt Ltd, Mumbai and Director Solutions, Thane, India

Dr Ahmed Ezat El Zowalaty has a PhD in Toxicology from University of Georgia, USA under direction of Prof. Dr. Xiaoqin Ye, a world-expert in GPCR signaling and LPA3 signaling. Dr. Ahmed El Zowalaty did postdoctoral research at Sahlgrenska Center for Cancer Research, Wallenberg Centre for Molecular and Translational Medicine at University of Gothenburg, Sweden under direction of Dr. Volkan Sayin. Dr Ahmed El Zowalaty has experience in redox biology, bioinformatics, cancer biology and pharmacy. He has published more than 20 publications in international peer reviewed journals. He has been invited as speaker to deliver speeches in international meetings including the SSR annual meeting. His research focuses on understanding molecular mechanisms of carcinogenesis and identifying novel therapeutic targets and treatments.

Over 35 yrs in pharma industry in medical department,

Responsible for Clinical research, regulatory & medicomarketing and pharmacovigilance in companies like Sarabhai, Cipla, FDC, Cyanamid/Wyeth, Organon, in local and regional roles

BSc Chemistry Graduate, MSc Organic Chemistry Student, specialized in Computational Drug Design, Molecular Dynamics and NMR experiments.

I am a hard-working, creative and motivated person interesting to learn new things. I like to combine science so I have knowledge both in Organic Synthesis by my undergraduate thesis and in Computational Organic Chemistry by my master thesis. I am very collaborated person with teamwork spirit.

All in all, utilizing the experience I’ve gained, I am ready to apply my skills and laboratory experience in my career in the field of chemistry. My goal is to contribute with my knowledge and skills to the implementation and development of science.

Prof. Omayma A. Eldahshan

Prof. and Head of Pharmacognosy, Faculty of Pharmacy, Ain Shams University

• Member in Technical Committee for Herbal Plants in Egyptian Organization for Standards & Quality
• Member in ARSO TC 82 African Traditional Medicine in African Organization for Standardization ARSO
• Three projects participation, STDF (investigator), PI (Ain Shams post grad Project) and community affairs Ain shams university (investigator).
• 23 scientific conferences (attendance, participation and speaker) and 14 workshops
• 29 master and doctoral theses
• 15 Discussion and approval of master and PhD Theses
• 5 Book Chapters
• 92 International Publications
• Editorial members in 13 International Journals
• Reviewer in STDF and 12 international journals

I graduated in Biomedicine at the Federal University of Minas Gerais (UFMG) and during my graduation I received two awards of academic relevance, two honorable mentions, and a first-place award for research carried out during two years of scientific initiation. During this period, I did my Master's in Clinical and Toxicological Analysis at UFMG, and also participated in congresses and co-supervised an undergraduate student. Currently I am finishing my PhD in Pharmaceutical Sciences, also from UFMG and I have a total of 12 articles published in several journals, 3 of them as first author. During this time, I have also been a member of two undergraduate advisory boards. Besides, I am interested in scientific events, among courses, symposia and congresses, with ten papers submitted.

Research interests

• Preparation and characterization for nanosystems.
• Evaluation of Cancer’s treatment.
• Tests of drug toxicity, in vitro and in vivo.
• Studies by radiolabeled, biodistribution and clearence for radiotracer.
• Works with cell culture.

Radhwan Al-Zidan is a Specialist Pharmacist. He has more than twelve years of professional experience arising from working as a Hospital Pharmacist, a Community Pharmacist, and from his current position in Academia. After specializing in Medical Biotechnology, Radhwan was promoted to Assistant Lecturer in the College of Pharmacy / University of Mosul. Furthermore, he has been served as a member of the Scientific Committee in the syndicate of the pharmacists-Nineveh branch. In 2021, he has been granted a permanent position as a lecturer in the College of Pharmacy.

Radhwan won the prize of “Academic Excellence” from the Ministry of Higher Education and Scientific Research (MOHESR) in Iraq, for graduating third among all of the Iraqi pharmacists in 2010. Additionally, Radhwan got a scholarship, in 2014, from the HCED to study for masters in the United Kingdom. During his study in the UK, he won the MESPAS award from the British Society for Immunology. Also, Radhwan graduated first on his peers in the masters and won the “Class Medal” from Edinburgh Napier University. At the beginning of 2020, his book “Drugs in Pregnancy: A Handbook for Pharmacists and Physicians” won first place in the "Iraqi Science Day" award. Furthermore, he has several published articles in renowned journals.

Research interests

• Drug safety
• Biotechnology
• Clinical Pharmacy
• Quality control of marketed drugs
• Dosage form design

Okiemute Rosa Johnson-Ajinwo obtained her BSc in Pure and Industrial Chemistry from the Nnamdi Azikiwe University, Awka, Anambra state, Nigeria in 1998 and proceeded to the University of Port Harcourt in 2000, for a Master’s degree in Analytical Chemistry. By 2006, she joined the Department of Pharmaceutical/Medicinal Chemistry of the Faculty of Pharmaceutical Sciences in the University of Port Harcourt as a Lecturer 11. The following year, she commenced studies at the University of Nigeria, Nsukka, Enugu state, Nigeria for a Masters’ degree in Pharmaceutical Chemistry. By 2017, Rosa obtained her PhD in Pharmacy from the Keele University, UK. Rosa is a beneficiary of five scholarship awards, notably amongst which are: (i) SPDC( Shell Petroleum Development Company), Scholarship award for Undergraduate study, 1995. (ii) McArthur Grant for MSc study, 2008, and (iii) ETF (Education Tax Fund, now known as TETFUND) Scholarship award for PhD study in the UK, 2011. She is also a recipient of several student awards such as; (i) Frank and Mary Loewus Student Travel Award from Phytochemical Society of North America, PSNA, 2015, 54th Annual Meeting. (ii) Best Poster Award from Phytochemical Society of North America, PSNA, 2015, 54th Annual Meeting and (iii) Keele Postgraduate Association, (KPA) Bursary Award, 20th May, 2015. Currently, she is a Senior Lecturer and the Head of Department of Pharmaceutical/Medicinal Chemistry of the Faculty of Pharmaceutical Sciences at the University of Port Harcourt, Rivers State, Nigeria.

Awofisayo,Oladoja A.(Mrs). was awarded Bachelor of Pharmacy(B.Pharm) degree in 1995(University of Ibadan,Nigeria).She had her internship training in the Pharmacy department of the Obafemi Awolowo University Teaching Hospital,Ile-Ife Nigeria in 1996.She served in the Cottage Hospital,Nassarawa-eggon,Nassarawa state as Youth Corp Pharmacist under the National Youth Service Scheme in 1997. She was appointed an assistant lecturer in the Faculty of pharmacy, University of Uyo. Her Master's degree(M.Sc.) was obtained in 2003 in Pharmaceutical chemistry (Pharmaceutical analysis option) from the University of Ibadan,Nigeria. She worked in the SuperComputingFacility for Bioinformatics SCFBio IITD in New Dehli, India between 2011 and 2013. She was awarded doctoral degree. in Pharmaceutical and Medicinal chemistry with a focus on receptor-ligand binding techniques in the development of novel drugs. She is also focused on disease conditions that can impact the kidney and research into drugs for Covid-19 viral and variants treatment.

Dr. Sanchez-Magraner obtained her BSc degree in Biochemistry from the University of La Habana, Cuba. She later moved to Spain, where she obtained her PhD. in Biochemistry and Molecular Biology from the University of the Basque Country. She has received several post-doctoral grants from different institutions such as Spanish National Research Council (CSIC), the University of the Basque Country and the Basque Government. Her work has been focused on protein biophysics and biomarkers development for oncology and it has contributed to clarify the role of different domains of certain proteins with regards to their structure and function, as well as the development of new biomarkers for immuno-oncology. Since 2017, Lissete has been the Senior Scientist and Project Manager at FASTBASE Solutions. She has 15 relevant peer-reviewed scientific publications and book chapters, one patent and has participated in more than 20 research projects granted by public bodies.

Dr Tianbao Chen is a Professor in Natural Drug Discovery at the School of Pharmacy, Queen’s University Belfast, UK. His research interests are focused on studying the proteins/peptides that occur in the venoms of many venomous species and the genes that encode them, with the view to finding new drug leads. Also his work involves finding and characterising biologically active agents within Nature, such as venom from frogs and toads, which can help in the treatment of major diseases and lead to the development of new therapeutics. His research is characterized by a fusion of biochemistry and cell and molecular biology.

Research Interest:

• Drug discovery and design
• Natural medicines
• Venoms and toxins
• Peptides and protein
• Molecular biology
• Pharmacology

University of chonnam national university, South Korea

Dr. Giuseppe Lanza is currently Associate Professor and Dean of Applied Medical Sciences Techniques at the University of Catania (Italy). After graduation with honours in Medicine, he trained at the School of Neurology and he got the international PhD. As Clinical Research Fellow, he further trained in Clinical Neurophysiology at the Newcastle University (UK). More recently, he has obtained the Master of Science in Clinical Research and the National Scientific Qualification as Full Professor. He is also Consultant Neurologist at the Oasi Research Institute–IRCCS in Troina (Italy), a WHO Collaborating Center, where he also coordinates a Research Unit. He authored >180 scientific publications and serves as Editor and Reviewer of several international Journals.

Prof. Shazi Shakil's profile has a global rank #1 in 'Protein ligand docking' on GOOGLE SCHOLAR, available at the link:
https://scholar.google.com/citations?view_op=search_authors&hl=en&mauthors=label:protein_li
gand_docking with a total number of scientific citations as 4149 (as noted on 10 May 2022). Total number of publications authored by Prof. Shazi is over 100. He has an h-index of 29 and i10 index of 61 and has worked on many big and small projects. His designation is ‘Profes sor’ at King Abdulaziz University, KSA. Dr. Shazi Shakil's research thrust encompasses: Enzoinformatics (Bioinformatics) and Microbiology. Core thrust area is Protein Ligand Docking. He obtained his PhD in Biotechnology from AMU (India) along with the “Mos t Active Researcher Award”. He has previously served at KFMRC, KAU, KSA and Integral University, India as Assistant Prof and Assoc Prof. His name appeared in Marquis Who’s Who in the World, (31st Edition). He is editor in International indexed journals. He has guided dissertations of 1 Phd, 4 Masters and 12 Graduate students to completion. He is UGC-CSIR-NET, DBT-JRF, GATE (TWICE) qualified (98.3 percentile). He is a recipient of awards from various bodies like AFMI (USA), Bharat Vikas Parishad and CEPECAMI, India. Research thrust is on computational enzyme-ligand interactionstudies (human neuroenzymes, bacterial drug resistance enzymes etc). He has coined the term ‘Enzoinformatics’.

Link to his google scholar profile is:
https://scholar.google.com/citations?user=gURcbbgAAAAJ&hl=en

Dr. Nagwa Ali Sabri is a Professor of Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Egypt. She was a Head of Clinical Pharmacy Department from 2014 to 2021 and has a Diploma in Medical Informatics from SIRA Institute, USA., IRCA Certified Auditor ISO 9001:2015 and Certified Pharmacovigilance Specialist (Qualified Person for Pharmacovigilance (QPPV). She is an ex- director of She is a Principal Investigator and member of institutional review board of Drug Research Centre (Bioequivalence and Pharmaceutical Research Centre, Cairo-Egypt). Member in Biocides Technical Committee of Ministry of Health. Dr. Nagwa’s areas of interest include; teaching, supervising different activities of under and post-graduate students, investment of clinical pharmacy activities in community pharmacies and hospitals. She shared in a number of projects of ain shams university. She has more than 31 years of academic experience, and more than 29 years of experience in advanced pharmaceutical and clinical research, being principal investigator in about 480 clinical and pharmaceutical studies. She shared as a member in several educational and post graduate committees for establishment of undergraduate and post-graduate curriculums including clinical pharmacy and pharm.D. She owns a significant experience in establishment of quality assurance systems and advanced training schedule in Clinical Pharmacy. She has about 160 published researches and more than 30 national and international awards and prizes.

Research Interests

• Clinical Pharmacy Practice and Pharmacotherapy.
• Quality Assurance Systems, Certification and Accreditaion.
• Bioequivalence, Pharmacokinetics/Pharmacodynamics modelling, and Clinical Pharmacokinetics.
• Pharmacovigilance, Pharmacogenomic and Pharmacogenetics.
• Clinical Trials.
• Pharmaceutics, drug formulation, in vitro testing (dissolution, disintegration, weight variation,…etc).
• Analytical and Bio-analytical Method development (including; method validation, analysis) and its application in the pharmaceutical products and different body fluids.

Stanislav Kotlyarov was educated as a medical doctor in 2007 and received his PhD in 2011. His thesis was on "Structure of respiratory symptoms and spirometry screening in the assessment of chronic obstructive pulmonary disease at the primary treatment level". He works at Ryazan State Medical University as head of the department. He is board-certified as a general practitioner and family medicine physician. Was involved in clinical trials of medicines and medical devices. He has over 50 publications, including several articles in leading international peer-reviewed journals. He is a frequent speaker at international conferences. Areas of research interests: molecular immunology, molecular pharmacology of respiratory and cardiac diseases.

Research interests: respiratory medicine; atherosclerosis; metabolism; innate immunity; inflammation; molecular immunology; molecular pharmacology

My name is Sashi Debnath and I currently work as a postdoctoral research fellow in the Department of Radiology, at the University of Texas Southwestern Medical Center. I completed my Ph.D. in Synthesis of 𝜋-conjugated Building Blocks in 2017 from Indian Institute of Science Education and Research (IISER) Kolkata, India. During my PhD, I joined as a visiting research fellow (IUSSTF) at the University of Massachusetts-Amherst in 2016 and developed π-conjugated radical anion polymers. After PhD, I pursued a postdoctoral fellowship from the Katholieke Universiteit Leuven, Belgium, where my research focus represent development of polymeric nanoparticles for targeted and controlled drug delivery.

I joined as a postdoctoral researcher in Dr. Xiankai Sun’s team in the Department of Radiology at the University of Texas Southwestern Medical Center (Dallas, TX) (March 2018 – present). In this position, I improved my expertise in a modern area of molecular imaging research, focusing on radiolabeling of small molecules and drug conjugates for cancer imaging and therapy. I am an experienced radiochemist with extensive knowledge of organic synthesis. Skilled in preclinical and clinical research for the development of PET-drugs and theranostic drug conjugates focusing on 18F, 11C, 125I, 68Ga, 64Cu, and 67Cu radiochemistry. In addition, I have expertise in Cyclotron-based PET drug synthesis for clinical evaluation of IND and FDA permitted tracers.

One of my foremost project involved the synthesis of radiolabeled PT2385 drug molecules with 18F and 11C radioisotope and their testing as diagnostic agents for PET/CT imaging of kidney cancer (https://patentimages.storage.googleapis.com/52/e3/e8/97657659e5b276/US20210190788A1.pdf) (https://aacrjournals.org/cancerres/article/82/12_Supplement/2478/704395). I validate the radiosynthesis of 18F-PT2385 PET drug in an automated synthetic module for translational purposes. We have received 18F-PT2385 FDA-IND approval for the diagnosis of kidney cancer and the human trial is on track at the University of Texas Southwestern Medical Center (https://clinicaltrials.gov/ct2/show/NCT04989959).

I also lead other projects involved the synthesis of radiolabeled (18F, 68Ga, 64Cu based) small-molecule drug conjugates and implemented as a diagnostic agent for PET/CT imaging in prostate and neuroendocrine prostate cancer (International (PCT) Application No. PCT-US2021-055885 Filed). Some of the preclinical results were presented at Society of Nuclear Medicine and Molecular Imaging conference 2019 and 2020 (https://jnm.snmjournals.org/content/60/supplement_1/1622, https://jnm.snmjournals.org/content/61/supplement_1/1108). Our patent application for Proinflammatory prodrugs is under provisional period with US patent application number US 63/093,964.

On the other hand, I assist in Mediso PET/SPECT/CT scanner for preclinical imaging experiments and create imaging protocols to validate imaging agents for cancer diagnosis. Other than conducting research, during my tenure as a researcher, I have also mentored students, trained newer lab members, and have assisted my advisors for research proposals and grant applications. I wish to continue my contribution towards the betterment of cancer research by being a part of this cutting-edge science.